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MYELOID NEOPLASIA
Brief report
Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of
acute myeloid leukemia with a distinctive gene expression profile that is uniquely
associated with a favorable outcome
Bas J. Wouters,1 Bob Lo¨wenberg,1 Claudia A. J. Erpelinck-Verschueren,1 Wim L. J. van Putten,2 Peter J. M. Valk,1 and
Ruud Delwel1
Departments of 1Hematology and 2Trials and Statistics, Erasmus University Medical Center, Rotterdam, The Netherlands
Mutations in CCAAT/enhancer binding
protein  (CEBPA) are seen in 5% to
14% of acute myeloid leukemia (AML)
and have been associated with a favor-
able clinical outcome. Most AMLs with
CEBPA mutations simultaneously carry
2 mutations (CEBPAdouble-mut), usually
biallelic, whereas single heterozygous
mutations (CEBPAsingle-mut) are less fre-
quently seen. Using denaturing high-
performance liquid chromatography and
nucleotide sequencing, we identified
among a cohort of 598 newly diag-
nosed AMLs a subset of 41 CEBPA
mutant cases (28 CEBPAdouble-mut and
13 CEBPAsingle-mut cases). CEBPAdouble-mut
associated with a unique gene expres-
sion profile as well as favorable overall
and event-free survival, retained in multi-
variable analysis that included cytoge-
netic risk, FLT3-ITD and NPM1 mutation,
white blood cell count, and age. In con-
trast, CEBPAsingle-mut AMLs did not ex-
press a discriminating signature and
could not be distinguished from wild-type
cases as regards clinical outcome. These
results demonstrate significant underly-
ing heterogeneity within CEBPA mutation-
positive AML with prognostic relevance.
(Blood. 2009;113:3088-3091)
Introduction
Mutations in the transcription factor CCAAT/enhancer binding protein
 (CEBPA) are found in 5% to 14% of acute myeloid leukemia
(AML).1-9 CEBPA mutations have been associated with a relatively
favorable outcome and have therefore gained interest as a prognostic
marker.4-6,10 Although variable sequence variations have been described,
2 prototypical classes of mutations are most frequent. N-terminal
mutations are located between the major translational start codon and a
secondATG in the same open reading frame. These mutations introduce
a premature stop of translation of the p42 CEBPA protein while
preserving translation of a p30 isoform that has been reported to inhibit
the function of full-length protein.2 Mutations in the C-terminal basic
leucine zipper (bZIP) region, in contrast, are in-frame and may impair
DNA binding and/or homodimerization and heterodimerization.8 The
remaining mutations are mostly found between the N-terminus and the
bZIP region.11
Most CEBPA mutant AMLs exhibit 2 mutations, which most
frequently involves a combination of an N-terminal and a bZIP
gene mutation.7,8,11,12 In AMLs with 2 CEBPA mutations, the
mutations are typically on different alleles.11 Hence, in these cases,
no wild-type CEBPA protein is expressed. A similar condition is
found in AMLs carrying a homozygous CEBPA mutation.13 How-
ever, there are also AMLs that only show one single heterozygous
mutation and thus retain expression of a wild-type allele.7,11,12
To obtain better insight into the distribution of the various types of
CEBPA mutations in de novo adult AML and their impact on clinical
outcome, we examined a cohort of 598 cases. After denaturing high-
performance liquid chromatography (dHPLC) and nucleotide sequenc-
ing, we distinguished cases with 2 different mutations or one homozy-
gous mutation (further referred to as double mutations; CEBPAdouble-mut)
as well as cases with only one single heterozygous mutation
(CEBPAsingle-mut). Genome-wide gene expression profiling revealed
that CEBPAdouble-mut AMLs expressed a highly characteristic signa-
ture, whereas CEBPAsingle-mut cases did not. In addition, favorable
prognosis appeared uniquely associated with CEBPAdouble-mut AML.
Methods
AML samples, mRNA isolation, dHPLC analysis, and nucleotide
sequencing
Bone marrow aspirates or peripheral blood samples of 598 cases of de novoAML
were collected, blast cells were purified, and mRNA was isolated as reported.14
The entire CEBPA coding region was investigated by dHPLC and selected
regions also by agarose gel analysis and/or nucleotide sequencing. For details on
patient characteristics and experimental procedures, see Document S1 (available
on the Blood website; see the Supplemental Materials link at the top of the online
article). All studies were approved by the Erasmus University Medical Center
Institutional Review Board (Rotterdam, The Netherlands), and patients’informed
consent was obtained in accordance with the Declaration of Helsinki.
Statistical analysis
Survival was estimated according to the method of Kaplan and Meier. The
log rank test was used to assess statistical significance. Multivariable
analysis was performed using Cox proportional hazards models. Definitions
of outcome parameters and cytogenetic risk groups have been described.15
Further details are given in Document S1. P values less than .05 were
considered statistically significant.
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Gene expression profiling analysis
Gene expression profiles were obtained using Affymetrix (Santa Clara, CA)
HGU133Plus2.0 GeneChips. Details on data processing and analysis are
given in Document S1.
Results and discussion
In a cohort of 598 cases of adult de novo AML, we identified 65 cases
with an aberrant profile in at least 1 of the 3 investigated amplicons of
the CEBPA coding sequence (Figure 1A,B). The presence of a CEBPA
sequence variation was confirmed by nucleotide sequencing. Cases that
only carried an insertion polymorphism16,17 or variation(s) that did not
lead to amino acid changes were considered wild-type. Two additional
specimens were not considered in further analysis because they carried
in-frame variations of unknown significance in the N-terminus
(Table S1). As a result, 41 of 598 unambiguous CEBPAmut AML
cases (6.9%) were considered. These included 13 CEBPAsingle-mut
cases and 28 CEBPAdouble-mut cases. Four of the CEBPAdouble-mut
cases carried homozygous mutations, whereas the remaining
24 cases showed 2 heterozygous mutations (Table S1). Additional
screening of the remaining AML cases, using a combination of
agarose gel analysis and nucleotide sequencing as described,6 did
not reveal mutations that had been missed by dHPLC.
To investigate whether CEBPA mutations related to gene expression,
we examined genome-wide gene expression data of 524 AML cases,
which included 26 CEBPAdouble-mut and 12 CEBPAsingle-mut cases. Clinical
and molecular characteristics of theAMLcases are reported in Tables S4
and S5. Using prediction analysis for microarrays,18 according to a
supervised approach, we derived a 19-probe set signature predictive of
CEBPA mutations (Figure 1C). This classifier showed a high specificity
(99%) but a limited sensitivity (67%) in cross-validation, indicating a
limited ability to recognize all CEBPAmut specimens. Strikingly, misclas-
sification was almost entirely the result of CEBPAsingle-mut cases, whereas
CEBPAdouble-mut AMLs were predicted with an accuracy that was near
perfect (Figures 1C, S1). In line with this, we were able to derive a
specific 21-probe set classifier for CEBPAdouble-mut AMLs within the
entire AML cohort with a cross-validated sensitivity of 100% (specific-
ity, 98%; Table S3). In further support, unsupervised analysis of the
expression data derived from the CEBPAmut subset indicated an underly-
ing variability in gene expression that correlated with either double or
single mutation status (Figure S2).
Figure 1. Schematic overview of dHPLC analysis, gene expression profiling analysis, and survival estimates. (A) Schematic representation of the CEBPA gene and
location of amplicons a, b, and c for polymerase chain reaction, used for dHPLC analysis. Functional regions are depicted: 2 transactivation domains (TAD1 and TAD2) in the
N-terminal part, and the bZIP region in the C-terminal part. Nucleotide (nt) position is indicated relative to the main translation start site. Amino acid (aa) numbering and the
alternative translation start site at position nt 358 (aa 120) are also depicted. (B) Representative profiles of dHPLC analysis of 1 of the 3 investigated fragments (ie, amplicons b)
in a random selection of approximately 90 samples. Heteroduplexes (various colors) are released earlier than homoduplexes (green) and can therefore be recognized as
distinct peaks. Time is depicted on the x-axis, and absorbance on the y-axis. (C) A gene expression prediction signature for CEBPAmut AML (irrespective of single- or
double-mutant status) was derived in a dataset of 524 AMLs, including 38 CEBPAmut cases. Prediction accuracy for each of the 38 CEBPAmut cases was estimated using
repeated 10-fold cross-validation, as detailed in supplemental data. The proportion of correct predictions for the selected 38 CEBPAmut specimens is indicated (top panel).
Mutation status is color coded (CEBPAsingle-mut, blue; CEBPAdouble-mut, red). The heatmap in the bottom panel depicts the 19 probe sets in the resulting CEBPAmut gene
expression classifier (Table S2, probe set information). Intensity values (log2) were mean centered over the cohort of 524 AML cases; and for visualization purposes, the genes
were hierarchically clustered (Euclidian distance, average linkage). Cells represent relative log 2 expression values and have been color coded on a scale ranging from bright
green (3) to bright red (3), with black indicating no change relative to the mean. (D) Kaplan-Meier estimates of overall survival among CEBPAmut and CEBPAwt AML (log rank
test, P  .027). (E) Overall survival among CEBPAdouble-mut versus CEBPAwt AML (P  .004) and versus CEBPAsingle-mut AML (P  .005; pooled P  .012). (F) Event-free
survival (EFS) among CEBPAdouble-mut and CEBPAwt AML (P  .005) and versus CEBPAsingle-mut AML (P  .004; pooled P  .008). The cumulative proportion of survival at the
intercept (the point where a line crosses the y-axis) reflects the proportion of patients reaching complete remission. Analyses similar to those depicted in panels D-F were
performed after splitting the group of CEBPAwt AMLs into those with favorable cytogenetics and those with other cytogenetics. These additional analyses can be found in Figure S4.
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We next assessed how these differences between CEBPAdouble-mut and
CEBPAsingle-mut related to clinical outcome. In line with previous data,
overall survival and event-free survival were significantly better for
CEBPAmut cases compared with cases with wild-type CEBPA (CEB-
PAwt) (Figure 1D; and data not shown). Separate analyses for the
CEBPAdouble-mut and CEBPAsingle-mut subgroups, however, revealed a
favorable outcome that was specific for CEBPAdouble-mut cases. We failed
to find a favorable prognostic effect in relation to the CEBPAsingle-mut
cases. Indeed, CEBPAsingle-mut AMLs showed a significantly worse
outcome than CEBPAdouble-mut cases, including a poor rate of complete
remission (Figure 1E,F). These findings were also apparent in multivari-
able analysis (Table 1). When only patients younger than 60 years or
only patients with normal cytogenetics were considered, similar results
were found, although in the latter subgroup with smaller numbers only
the pairwise comparison for overall survival between CEBPAdouble-mut
and CEBPAsingle-mut reached statistical significance (Figure S3; Table S6).
Based on our previous analyses6 and on the literature,11 it is
probable that, in the majority of the CEBPAdouble-mut AML
studied, both CEBPA alleles were affected. A plausible hypoth-
esis is therefore that absence of wild-type CEBPA mRNA is
directly involved in the CEBPAdouble-mut gene expression profile.
This may be further supported by our previous and current
observations that indicate a high degree of similarity between
the profiles of CEBPAdouble-mut AML and a specific subgroup of
leukemias characterized by epigenetic CEBPA silencing (Figure
S1).19 It is possible that analysis of larger patient series will lead
to further refinement of this subclassification, for instance,
based on the location of the mutations. For example, our data
indicated a tendency of CEBPAsingle-mut cases with mutations in
the bZIP region to be potentially less distinct from the
CEBPAdouble-mut AMLs (case nos. 7185, 7324, and 2237; Figures
1C, S2). Of note, a subset of the CEBPAmut AMLs studied here
was included in the cohort of 285 cases of AML that we
previously investigated by gene expression profiling.14 In that
study, all CEBPAdouble-mut AMLs were found in 2 particular
clusters, whereas CEBPAsingle-mut AMLs did not specifically
aggregate.14,19
Studies to date have associated CEBPA mutations with outcome4-6,9
but have not applied subdivisions into single and double mutants. It is
unclear why CEBPAdouble-mut AMLs would have a better outcome than
those with a single heterozygous mutation. One explanation could be
that a single-mutant CEBPA allele is not sufficient for leukemogenesis
and requires cooperating mutations, which may be in CEBPA itself or in
other genes. Of note, recent data indicate that germline CEBPA
mutations predispose to AML, and the acquisition of a second, somatic
CEBPA mutation may then contribute to AML development.20 Indeed,
we found a tendency toward more FLT3-ITD, FLT3-TKD, and NPM1
mutations in CEBPAsingle-mut compared with CEBPAdouble-mut cases (Table
S5). Yet unknown abnormalities may associate with CEBPAsingle-mut
AML as well and predispose to inferior outcome. It is however evident
that these findings and their clinical significance warrant confirmation in
independent cohorts of AML.
In conclusion, the data presented here indicate that CEBPAmut
AML should at least be distinguished according to the presence of
CEBPAdouble-mut and CEBPAsingle-mut. Screening using dHPLC, fol-
lowed by nucleotide sequencing, appears useful for rapidly identi-
fying mutant cases. In addition, gene expression-based classifica-
tion, for instance, using the classifiers described here, enables the
accurate identification of CEBPAdouble-mut AML cases.
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Table 1. Multivariable analysis of CEBPAdouble-mut and CEBPAsingle-mut as prognostic markers for overall and event-free survival
Variable
Overall survival Event-free survival
HR (95% CI) P HR (95% CI) P
CEBPAsingle-mut* 1.18 (0.58-2.40) .65 1.61 (0.82-3.17) .16
CEBPAdouble-mut* 0.32 (0.17-0.61)  .001 0.35 (0.20-0.62)  .001
Intermediate† 2.21 (1.52-3.22)  .001 2.05 (1.46-2.87)  .001
Poor† 3.35 (2.27-4.94)  .001 2.85 (2.00-4.06)  .001
Age, decades 1.17 (1.08-1.28)  .001 1.10 (1.02-1.19) .014
WBC‡ 1.33 (1.05-1.68) .019 1.29 (1.03-1.62) .025
FLT3 ITD§ 1.56 (1.20-2.03)  .001 1.46 (1.14-1.89) .003
NPM1 mutation 0.55 (0.41-0.74)  .001 0.51 (0.39-0.67)  .001
Complete data for multivariable analysis were available for 511 cases.
HR indicates hazard ratio; CI, confidence interval; WBC, white blood cell count; FLT3, fms-related tyrosine kinase 3; ITD, internal tandem duplication; and NPM1,
nucleophosmin.
*CEBPA status versus CEBPAwt.
†Cytogenetic risk versus cytogenetic good risk.
‡WBC greater than 20  109/L versus less than 20  109/L.
§FLT3 ITD versus no FLT3 ITD.
NPMI mutation versus no NPMI mutation.
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